Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotype-driven NPC1L1 and PCSK9 inhibition and reduced risk of periodontitis.

Journal of clinical periodontology - 1 Jan 2023

Baumeister Sebastian-Edgar, Holtfreter Birte, Reckelkamm Stefan Lars, Kocher Thomas, Alayash Zoheir, Ehmke Benjamin, Baurecht Hansjörg, Nolde Michael

Abstract excerpt

AIM: Epidemiological and pre-clinical studies suggest a chemoprotective role of lipid-lowering agents in periodontitis. We tested the association of genetically proxied inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), Niemann-Pick C1-Like 1 (NPC1L1) and proprotein convertase subtilisin/kexin type 9 (PCSK9) with periodontitis. MATERIALS AND METHODS: Genetic variants in HMGCR, NCP1L1 and PCSK9...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholesterol, LDL
Share to Genome-Wide Association Study

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genotype

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Membrane Transport Proteins

Share to Periodontitis

Share to Proprotein Convertase 9

Source

Identifiers

PMID: 36054135
DOI: 10.1111/jcpe.13719

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotype-driven NPC1L1 and PCSK9 inhibition and reduced risk of periodontitis.PMID 36054135Read ↗

Complement C3 as a potential drug target in periodontitis: Evidence from the cis-Mendelian randomization approach.Semantic proximity Read ↗

Using human genetics to validate complement C3 as a drug target in periodontitisSemantic proximity Read ↗

Associations of Lipid-Lowering Drugs With Blood Pressure and Fasting Glucose: A Mendelian Randomization Study.Semantic proximity Read ↗

Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.Semantic proximity Read ↗

Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: a Mendelian randomization studySemantic proximity Read ↗

Downregulation of interleukin 6 signaling might reduce the risk of periodontitis: a drug target Mendelian randomization studySemantic proximity Read ↗

Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.Semantic proximity Read ↗

Genetically proxied PCSK9 inhibition provides indication of lower prostate cancer risk: a Mendelian randomization studySemantic proximity Read ↗

Genomic Evidence on Antihypertensive Drug Targets and Oral Disease Outcomes.Semantic proximity Read ↗

Effects of genetically proxied statins on diabetic nephropathy and retinopathy: a Mendelian randomization study.Semantic proximity Read ↗

Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.Semantic proximity Read ↗

Genetic proxies for PCSK9 inhibition associate with lipoprotein(a): Effects on coronary artery disease and ischemic strokeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.